Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Aggressive B-cell Lymphomas in the CAR T Era

Scientists selected patients with the following characteristics: CART or allogeneic hematopoietic cell transplantation (alloHCT) performed between 2016 and 2021; ≥18 years old; ABCL diagnosis; ≥2 lines of therapy; and either anti-CD19 CART or alloHCT as therapy at relapse. In the multivariate analysis, CART was confirmed to be similar to alloHCT for the primary study endpoint.